Lexicon Pharmaceuticals | LXRX - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Abbott USD 8.52B 1.01B 2025-12
Acadia Pharmaceuticals USD 819.69M 27.33M 2025-12
Agios Pharmaceuticals USD 89.13M 3.58M 2025-12
Akebia Therapeutics USD 184.84M 18.4M 2025-12
Alnylam Pharmaceuticals USD 1.66B 167M 2025-12
AstraZeneca USD 8.14B 1.08B 2025-09
BioMarin Pharmaceutical USD 1.31B 61.57M 2025-12
Coherus Biosciences USD 88.88M 14.47M 2025-12
Eli Lilly USD 7.27B 2.52B 2025-12
Esperion Therapeutics USD 92.45M 6.39M 2025-09
Halozyme Therapeutics USD 133.82M 285.84M 2025-12
Illumina USD 1.42B 368M 2025-12
Insmed USD 510.44M 175.68M 2025-12
Ironwood Pharmaceuticals USD 140.41M 47.56M 2025-09
J&J USD 19.71B 1.48B 2025-12
Lexicon Pharmaceuticals USD 21.36M 41.52M 2025-06
MacroGenics USD 57.22M 22.91M 2025-12
MannKind USD 74.88M 52.51M 2025-12
Merck USD 18.17B 10.16B 2025-09
Moderna USD 2.6B 1.46B 2025-12
Novartis USD 9.56B 2.9B 2025-09
PTC Therapeutics USD 984.65M 312.03M 2025-12
Puma Biotechnology USD 53.52M 1.14M 2025-09
Sarepta Therapeutics USD 801.28M 188.2M 2025-12
Thermo Fisher Scientific USD 9.85B 7.87B 2025-12
Ultragenyx Pharmaceutical USD 202.51M 36.4M 2025-09
United Therapeutics USD 1.56B 217M 2025-12
Vanda Pharmaceuticals USD 84.85M 14.83M 2025-12